Jupiter Neurosciences, Inc. filed a Certificate of Amendment to its Delaware certificate of incorporation to effect a 1-for-75 reverse stock split of its common stock. The split became effective at 4:01 p.m. Eastern Time on August 6, 2026, with post-split trading commencing on the Nasdaq Capital Market on August 7, 2026. This action reduces outstanding shares from approximately 57.8 million to roughly 770,081 and aims to restore compliance with Nasdaq’s minimum bid price requirement. Fractional shares are cashed out based on the closing price on August 6, 2026. Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing therapies for neurological disorders.
